File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial

TitleEffect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trial
Authors
Issue Date2011
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ahj
Citation
American Heart Journal, 2011, v. 162 n. 5, p. 870-874 How to Cite?
Abstract
Background: Previous studies showed that esomeprazole does not interfere significantly with the platelet inhibitory effect of clopidogrel. It is unknown whether famotidine, a histamine 2 receptor antagonist, interacts with clopidogrel. This double-blind, randomized study aimed to compare the influence of esomeprazole and famotidine on the platelet inhibitory effect of clopidogrel. Methods: Patients with acute coronary syndrome or elective percutaneous coronary interventions treated with aspirin and clopidogrel cotherapy were randomized to receive esomeprazole 20 mg daily or famotidine 40 mg daily. Platelet reactivity units (PRUs) were measured at baseline and on day 28. The primary analysis involved the PRU values on day 28. Results: There were 44 patients in the esomeprazole group and 44 in the famotidine group. The baseline PRUs of the 2 groups were comparable (esomeprazole vs famotidine, 229.1 ± 85.6 vs 220.4 ± 83.0, P =.63). The PRUs on day 28 were 242.6 ± 89.7 and 237.5 ± 79.2 in the groups receiving esomeprazole and famotidine, respectively (mean difference 5.1, 95% CI -30.8 to 41.0, P =.78). Conclusions: The platelet inhibitory effect of clopidogrel was not significantly different between patients receiving esomeprazole and those receiving famotidine. Neither esomeprazole nor famotidine reduced the platelet inhibitory effect of clopidogrel. © 2011 Mosby, Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/159913
ISSN
2013 Impact Factor: 4.555
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTunggal, Pen_HK
dc.contributor.authorNg, FHen_HK
dc.contributor.authorLam, KFen_HK
dc.contributor.authorChan, FKLen_HK
dc.contributor.authorLau, YKen_HK
dc.date.accessioned2012-08-16T05:59:13Z-
dc.date.available2012-08-16T05:59:13Z-
dc.date.issued2011en_HK
dc.identifier.citationAmerican Heart Journal, 2011, v. 162 n. 5, p. 870-874en_HK
dc.identifier.issn0002-8703en_HK
dc.identifier.urihttp://hdl.handle.net/10722/159913-
dc.description.abstractBackground: Previous studies showed that esomeprazole does not interfere significantly with the platelet inhibitory effect of clopidogrel. It is unknown whether famotidine, a histamine 2 receptor antagonist, interacts with clopidogrel. This double-blind, randomized study aimed to compare the influence of esomeprazole and famotidine on the platelet inhibitory effect of clopidogrel. Methods: Patients with acute coronary syndrome or elective percutaneous coronary interventions treated with aspirin and clopidogrel cotherapy were randomized to receive esomeprazole 20 mg daily or famotidine 40 mg daily. Platelet reactivity units (PRUs) were measured at baseline and on day 28. The primary analysis involved the PRU values on day 28. Results: There were 44 patients in the esomeprazole group and 44 in the famotidine group. The baseline PRUs of the 2 groups were comparable (esomeprazole vs famotidine, 229.1 ± 85.6 vs 220.4 ± 83.0, P =.63). The PRUs on day 28 were 242.6 ± 89.7 and 237.5 ± 79.2 in the groups receiving esomeprazole and famotidine, respectively (mean difference 5.1, 95% CI -30.8 to 41.0, P =.78). Conclusions: The platelet inhibitory effect of clopidogrel was not significantly different between patients receiving esomeprazole and those receiving famotidine. Neither esomeprazole nor famotidine reduced the platelet inhibitory effect of clopidogrel. © 2011 Mosby, Inc. All rights reserved.en_HK
dc.languageengen_US
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/ahjen_HK
dc.relation.ispartofAmerican Heart Journalen_HK
dc.subject.meshAcute Coronary Syndrome - blood - drug therapy-
dc.subject.meshAnti-Ulcer Agents - administration and dosage-
dc.subject.meshFamotidine - administration and dosage-
dc.subject.meshOmeprazole - administration and dosage-
dc.subject.meshPlatelet Aggregation Inhibitors - administration and dosage-
dc.titleEffect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: A double-blind, randomized trialen_HK
dc.typeArticleen_HK
dc.identifier.emailLam, KF: hrntlkf@hkucc.hku.hken_HK
dc.identifier.authorityLam, KF=rp00718en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.ahj.2011.08.007en_HK
dc.identifier.pmid22093203en_HK
dc.identifier.scopuseid_2-s2.0-81255214744en_HK
dc.identifier.hkuros205610en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-81255214744&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume162en_HK
dc.identifier.issue5en_HK
dc.identifier.spage870en_HK
dc.identifier.epage874en_HK
dc.identifier.isiWOS:000297247800012-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridTunggal, P=54394619800en_HK
dc.identifier.scopusauthoridNg, FH=16936078000en_HK
dc.identifier.scopusauthoridLam, KF=8948421200en_HK
dc.identifier.scopusauthoridChan, FKL=7202586434en_HK
dc.identifier.scopusauthoridLau, YK=35765428400en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats